

Moxetumomab

Cat. No.:	HY-P99034
CAS No.:	1622075-65-3
Target:	ADC Antibody; CD22
Pathway:	Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Moxetumomab, a recombinant CD22-targeting immunotoxin, can be used for the research of hairy cell leukemia (HCL) ^{[1][2]} .
--------------------	--

REFERENCES

- [1]. Robert J Kreitman, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. *J Hematol Oncol.* 2021 Feb 24;14(1):35.
- [2]. Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. *Drugs.* 2018 Nov;78(16):1763-1767.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA